Rovalpituzumab Tesirine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rovalpituzumab Tesirine
Accession Number
DB13017
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
P256HB60FF
CAS number
1613313-09-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Rovalpituzumab Tesirine.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Rovalpituzumab Tesirine.
AbrilumabThe risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Rovalpituzumab Tesirine.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Rovalpituzumab Tesirine.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Rovalpituzumab Tesirine.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Rovalpituzumab Tesirine.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rovalpituzumab Tesirine.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Rovalpituzumab Tesirine.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Rovalpituzumab Tesirine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911416

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSmall Cell Lung Cancer (SCLC)2
1RecruitingTreatmentAdvanced Solid Tumors / Advanced Solid Tumors Cancer1
1TerminatedTreatmentSmall Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentRefractory Small cell lung cancer1
1, 2TerminatedTreatmentGlioblastomas / High Grade Gastroenteropancreatic Neuroendocrine Carcinoma / Large Cell Neuroendocrine Carcinoma / Medullary Thyroid Cancer (MTC) / Melanoma, Malignant / Neuroendocrine Carcinomas / Neuroendocrine Prostate Cancer / Other Neuroendocrine Carcinoma / Other Solid Tumors / Tumors, Solid1
2CompletedTreatmentMalignancies1
2CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
3CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
3TerminatedTreatmentSmall Cell Lung Cancer (SCLC)1
3WithdrawnTreatmentCancer - Small Cell Lung Cancer / Small Cell Lung Cancer (SCLC)1
Not AvailableNo Longer AvailableNot AvailableSmall Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 20:05 / Updated on March 01, 2020 21:23

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates